Aptevo Therapeutics (APVO) EBT (2015 - 2026)
Aptevo Therapeutics (APVO) posted EBT of -$7.2 million for Q1 2026, down 10.78% sequentially from -$6.5 million in Q4 2025, and down 5.23% YoY from -$7.6 million in Q1 2025.
Aptevo Therapeutics (APVO) EBT (2015 - 2026) Analysis & Trends
Aptevo Therapeutics has reported EBT for 12 years, with the latest figure at -$7.2 million in Q1 2026.
- Quarterly EBT fell 5.23% year-over-year to -$7.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$29.2 million (down 6.1% YoY) and the FY2025 annual result came in at -$32.3 million, down 1.05% from the prior year.
- EBT declined to -$7.2 million in Q1 2026 per APVO's latest filing, from -$6.5 million in the prior quarter.
- Over five years, EBT peaked at -$5.9 million in Q1 2022 and troughed at -$8.6 million in Q3 2025.
- A 5-year average of -$7.5 million and a median of -$7.4 million in 2023 frame the typical range for EBT.
- The widest YoY moves for EBT: up 47.15% in 2022, down 112.35% in 2022.
- Over 5 years, EBT stood at -$8.6 million in 2022, then grew by 12.22% to -$7.5 million in 2023, then declined by 3.01% to -$7.8 million in 2024, then gained by 16.45% to -$6.5 million in 2025, then decreased by 10.78% to -$7.2 million in 2026.
- According to Business Quant data, EBT over the past three periods registered -$7.2 million, -$6.5 million, and -$8.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | Aptevo Therapeutics | 3.30 Mn | -6.50 Mn | - | -6.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.13 Mn |
| Mar 31, 2026 | -7.18 Mn |
| Dec 31, 2025 | -6.48 Mn |
| Sep 30, 2025 | -8.64 Mn |
| Jun 30, 2025 | -6.91 Mn |
| Mar 31, 2025 | -6.82 Mn |
| Dec 31, 2024 | -7.76 Mn |
| Sep 30, 2024 | -6.25 Mn |
| Jun 30, 2024 | -6.71 Mn |
| Mar 31, 2024 | -7.33 Mn |
| Dec 31, 2023 | -7.53 Mn |
| Sep 30, 2023 | -7.36 Mn |
| Jun 30, 2023 | -8.64 Mn |
| Mar 31, 2023 | -7.87 Mn |
| Dec 31, 2022 | -8.58 Mn |
| Sep 30, 2022 | -8.56 Mn |
| Jun 30, 2022 | -8.11 Mn |
| Mar 31, 2022 | -5.93 Mn |
| Dec 31, 2021 | -4.04 Mn |
| Sep 30, 2021 | -6.01 Mn |